123 Main Street, New York, NY 10001

Top Navigation with Mega Menu

Co-Dx™ Logix Smart® ABC (influenza A/B, SARS-CoV-2) test kit

Boost speed and accuracy with real-time PCR testing

The Co-Dx Logix Smart ABC test kit is an in vitro diagnostic test that uses our patented Co-Primers™ technology for the qualitative detection of the RNA from the influenza A, influenza B, and SARS-CoV-2 viruses.

Woman in a medical setting testing a woman for influenza A, influenza B, and SARS-CoV-2 viruses, with a nasal swab

The power of multiplex

The multiplex test operates using a single step real-time reverse transcriptase PCR process in lower respiratory tract specimens (e.g. bronchoalveolar lavage, sputum, tracheal aspirate), upper respiratory tract specimens (e.g. nasopharyngeal, nasal, and oropharyngeal swabs), and saliva from individuals suspected of influenza A, influenza B, or COVID-19 and its related conditions.

Clickhereto read the Company’s regulatory bulletin on the ability of our suite of Co-Dx Logix Smart COVID-19 diagnostics to detect all known strains of SARS-CoV-2. 

Test kit components

The Co-Dx Logix Smart ABC test kit includes the following components.

Ready-to-use Master Mix

Includes the complete mix for convenience and an Internal Positive Control (IPC) - Human RNaseP gene marker

Positive Control

Synthetic control intended to amplify all targets included in the kit to ensure integrity of the entire run

Negative Control

Acts as a negative control to verify Master Mix is free from contamination

Additional information​

Positive results are indicative of the presence of influenza A, influenza B, and/or SARS-CoV-2 genomic material; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Many laboratories are required to report all positive results to the appropriate public health authorities.

Negative results do not preclude influenza A, influenza B, and/or SARS-CoV-2 infections and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The Co-Dx Logix Smart ABC test is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.

Test kit performance & specifications

SARS-CoV-2 Performance Characteristics

Qualitative Multiplex PCR test for detection and differentiation of influenza A, influenza B, and SARS-CoV-2

Influenza A

Influenza B


Limit of Detection
570 CEID50/mL
60.0 CEID50/mL
1000 copies/mL
93% (68-100%)
100% (78-100%)
100% (88-100%)
100% (88-100%)
100% (88-100%)
100% (88-100%)
Sample type
Lower respiratory samples (e.g. bronchoalveolar lavage, sputum, tracheal aspirate).
Upper respiratory samples (e.g. nasopharyngeal and oropharyngeal swabs), and saliva.
Time to detection
Approximately 90 minutes, depending on the instrument used
Thermal cycler
  • Co-Dx Box™ (Co-Diagnostics, Inc.)
  • MIC cycler (BMS, Biomolecular Systems)
  • ECO48 (PCR Max)
  • CFX96 (Bio-Rad)

The test should work with most qPCR systems with the following channel compatibilities:

  • FAM
  • CF560 (VIC)
  • CF610 (ROX)
  • QUASAR 670 (CY5)
Extraction kit compatibility
QIAamp® Viral RNA Mini Kit (Qiagen, CAT #52904, 52906)

* Sensitivity based on clinical study of 30 clinical remnant SARS-CoV-2 positive samples. 15 contrived influenza A samples. 15 contrived influenza B samples and 30 negative clinical remnant samples.

Request a quote​

Contact us for more information about the Co-Dx Logix Smart ABC test kit.

Get started

Every test from Co-Dx is designed to be easy to use.

Regulatory clearance

In November 2020, the Co-Dx Logix Smart ABC (influenza A/influenza B/COVID-19) test kit received CE marking approval, the principle regulatory clearance allowing the test to be sold as an in vitro diagnostic (IVD) for the diagnosis of COVID-19 in European Union states and other markets that accept a CE-IVD mark as valid regulatory approval.

Is this test FDA-approved or cleared?
No. This test is not yet approved or cleared by the U.S. Food and Drug Administration (FDA). This product is released for use as an in vitro diagnostic device, for export only and is not for sale in the United States.